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Abstract
Objective: The expression of FccRIIIa/CD16 may render monocytes targets for activation by IgG-containing immune
complexes (IC). We investigated whether FccRIIIa/CD16 was upregulated in rheumatoid arthritis (RA), associated with TNF
production in response to IC-stimulation, and if this predicted response to methotrexate therapy.
Methods: FccRIIIa/CD16 expression on CD14low and CD14++ monocytes was measured by flow cytometry in healthy
controls and RA patients (early and long-standing disease). Intracellular TNF-staining was carried out after in vitro LPS or
heat-aggregated immunoglobulin (HAG) activation. FccRIIIa/CD16 expression pre- and post-steroid/methotrexate treatment
was examined.
Results: Increased FccRIIIa/CD16 expression on CD14++ monocytes in long-standing RA patients compared to controls was
demonstrated (p = 0.002) with intermediate levels in early-RA patients. HAG-induced TNF-production in RA patients was
correlated with the percentage of CD14++ monocytes expressing FccRIIIa/CD16 (p,0.001). The percentage of CD14++
monocytes expressing FccRIIIa/CD16 at baseline in early DMARD-naı¨ve RA patients was negatively correlated with DAS28-
ESR improvement 14-weeks post-methotrexate therapy (p = 0.003) and was significantly increased in EULAR non-responders
compared to moderate (p = 0.01) or good responders (p = 0.003). FccRIIIa/CD16 expression was not correlated with age,
presence of systemic inflammation or autoantibody titers.
Conclusion: Increased FccRIIIa/CD16 expression on CD14++ monocytes in RA may result in a cell that has increased
responsiveness to IC-stimulation. This monocyte subset may contribute to non-response to methotrexate therapy.
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Introduction
IgG-containing immune complexes (IC), such as those contain-
ing rheumatoid factors (RFs) and cyclic citrullinated peptide (CCP)
autoantibodies, are found abundantly in serum and synovial fluid
of patients with rheumatoid arthritis (RA) [1,2]. ICs activate
various cell types following Fcc receptor (FccR) and complement
receptor binding and lead to a diverse range of effector functions.
FccRs play important roles in the initiation and regulation of
many immunological processes [3–5]. The importance of an
appropriate balance between activating and inhibitory FccRs in
the regulation of animal models of arthritis is well recognised [6,7].
A dominant role for FccRIIIa in IgG IC-mediated inflammatory
responses and in type I, II and III hypersensitivity reactions has
been highlighted in diverse animal models [8], including
autoantibody-induced arthritis [9]. FccRIIIa knockout mice are
protected from IC-induced arthritis [10,11] with FccRIIIa-
mediated mechanisms, but not complement, dominating in
promoting organ-specific destructive pathologies [12,13]. We have
recently demonstrated that genetic variation in FCGR3A is a risk
factor for the development of autoantibody-positive RA [14].
Cells of the monocyte/macrophage lineage play important roles
in RA pathogenesis, particularly the perpetuation of inflammation,
and are potential targets for activation by ICs. Activated
macrophages are the predominant infiltrating cell type found in
rheumatoid synovium, pannus and nodules [15,16]. FccR cross-
linking on macrophages potentially initiates phagocytosis, antigen
presentation, antibody-dependant cell-mediated cytotoxicity
(ADCC) and release of pro-inflammatory cytokines and tissue
destructive mediators [17]. The migration of monocytes from
blood to synovial tissue and their differentiation into macrophages
may be an important step in disease pathogenesis [18].
Macrophages are the major source of pro-inflammatory cytokines
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and chemokines in the inflamed RA joint, including tumour
necrosis factor (TNF), interleukin-1 (IL-1), interleukin-8 (IL-8) and
granulocyte-macrophage colony-stimulating factor (GM-CSF)
[15,19]. FccRIIIa cross-linking has been specifically implicated
in cytokine release from adherent human monocytes/macrophag-
es [20,21]. These cytokines are intimately involved in the disease
process as demonstrated by the clinical efficacy of TNF or IL-1
blockade in RA [22,23]. Osteoclasts, multinucleated giant cells
with the capacity to resorb bone, are also derived from a blood-
borne monocyte precursor and have been implicated in the
destructive disease process [24].
In human peripheral blood, monocyte subpopulations with
distinct functional properties have been defined by their expression
of CD14 and CD16 (FccRIIIa) [25,26]. Monocyte subsets were
initially defined as CD14low/CD16++ and CD14++/CD16neg/low
following work in healthy control subjects [27]. The CD14low
subpopulation accounts for approximately 7–10% of circulating
monocytes in healthy individuals. Recent studies have confirmed
that this is a distinct monocyte subpopulation resembling the
murine ‘‘patrolling’’ Gr1- monocytes, which appear to play a role
in immunosurveillance and the release of proinflammatory
cytokines, including TNF, in response to virally infected cells
and nucleic acids [26]. Previous studies have shown that the
numbers of CD14low monocytes are expanded during infectious
and inflammatory conditions, such as RA [28–31], however, this
finding has not been confirmed in all studies [32]. In contrast, the
‘‘classical’’ or ‘‘inflammatory’’ CD14++ monocyte subpopulation
that resembles murine Gr1+ monocytes was previously believed to
act as a phagocytic scavenger cell, removing apoptotic cells and
aiding in the resolution of inflammation [33]. More recent studies
have demonstrated reactive oxygen species production and
cytokine release in response to lipopolysaccharide (LPS) [26].
This cellular subset does not express FccRIIIa/CD16 under
normal conditions; however, levels are variable and can be
increased in inflammatory disease [6,34–37]. In RA, interest has
previously focussed on the CD14low subset due to the high
expression of FccRIIIa/CD16 and its ability to release TNF upon
activation [38]. However, these findings derive from observations
on healthy control cells and FccR-independent activators, such as
LPS [38]. The induction of proinflammatory cytokine release via
ICs cross-linking FccRIIIa/CD16 on monocytes/macrophages is
a possible additional mechanism for cellular activation in RA [39].
Various studies have demonstrated that IC, such as anti-CCP/
ACPA-containing IC [36,40] and collagen-containing IC [41], are
able to induce TNF production from monocytes/macrophages.
This has been demonstrated to be in a dose-dependent manner
[40]. Furthermore IC taken from serum and synovial fluid of RA
patients can induce TNF cytokine release from these cells [42]. It
remains unknown whether CD14++ monocytes can produce
substantially increased IC-stimulated TNF under inflammatory
conditions when FccRIIIa/CD16 expression is up regulated. In
addition, genetic polymorphism within FCGR3A whereby a valine
to phenylalanine substitution occurs (FCGR3A-158F/V) has been
shown to influence the affinity of the receptor for IgG. This may
also modulate activation through FccRIIIa/CD16.
We investigated whether monocytes from RA patients expressed
higher levels of FccRIIIa/CD16 resulting in a cell that is
potentially more sensitive to intravascular IC stimulation.
Furthermore, we explored whether upregulated FccRIIIa/CD16
expression was associated with modulation of monocyte functions
by assessing cytokine production following both LPS and IC
activation. We additionally hypothesised that upregulation of
FccRIIIa/CD16 in RA may be associated with a reduced response
to DMARD therapy, due to a persistent inflammatory drive.
Methotrexate remains the initial treatment of choice in RA, but is
widely recognised to fail to control disease activity in a sizeable
proportion of patients. The potential clinical significance of this
biological pathway was therefore evaluated in a cohort of
DMARD-naı¨ve RA patients receiving methotrexate as first-line
therapy.
Materials and Methods
Patients and controls
Adult RA patients (n = 38, mean age = 52 [range 27–80], 22
female) with long-standing disease (.2 years) who were taking
concurrent disease modifying anti-rheumatic drugs (DMARDs)
were recruited from rheumatology clinics in Leeds. Patients
fulfilled the 1987 American College of Rheumatology classification
criteria [43]. DMARD-naı¨ve early RA patients (n = 73, mean
age = 56 (range 29–78), 21 female) were recruited from the
Yorkshire Early Arthritis Register (symptom duration ,1 year).
Forty two patients were reviewed following methotrexate therapy
(10 mg weekly methotrexate, increasing stepwise to 20 mg by
week 4) with an initial bolus of systemic steroids (25 0mg IV
Methylprednisolone) for symptom control at initiation. Peripheral
blood samples were taken at baseline and following 2 and 14-
weeks of therapy. Blood samples were simultaneously obtained for
determination of CRP, ESR, anti-CCP and RF titres by routine
clinical laboratory methods. Four-variable DAS28-ESR scores
were determined at baseline and 14-weeks post-initiation of
therapy and used to define patient responses according to EULAR
response criteria (good, moderate or non-response). The presence
or absence of hand and foot erosions on X-ray at baseline was also
assessed. Healthy controls (n = 41, mean age= 44 (range 28–72),
18 female) were not experiencing any auto-inflammatory or
infectious events at time of blood donation. Additional elderly
control subjects with no concurrent inflammatory or infectious
diseases were recruited from either general rheumatology or
ophthalmology clinics (n = 21, mean age = 74 (range 55–90)). The
participants gave informed written consent in accordance with the
Declaration of Helsinki, and the study was approved by the
National Research Ethics Service Committee Yorkshire & The
Humber - Leeds East.
Flow cytometry
NH4Cl-lysed heparinised blood samples were incubated with
2 mg/ml normal human immunoglobulin (Novartis, Hanover,
Germany), to block non-specific binding for 30 min on ice. This
immunoglobulin concentration was chosen based on the maximal
human immunoglobulin concentration able to prevent non-
specific binding of IgG isotype control (Fig. S1A) while preserving
specific staining with anti-CD16 antibody (Fig. S1B). In 5 RA
patients and 3 healthy controls this immunoglobulin concentration
was demonstrated to have no detrimental effect on the CD16-PE
staining (Fig. S1C, with or without immunoglobulin p= 0.666).
Cells were stained (30 min, ice) with anti-CD16-PE (clone 3G8,
Caltag-Medsystems, Buckingham, UK) and anti-CD14-PerCP
(clone MwP9, BD Biosciences, Oxford, UK) or irrelevant isotype
controls. Cells were washed in phosphate buffered Saline
containing 0.5% bovine serum albumin and flow cytometry data
collected on FACSCalibur (Becton Dickinson, Oxford, UK).
Monocyte subsets were identified on the basis of forward scatter/
side scatter characteristics (FSC/SSC) and expression of CD14.
Separate gates were created around CD14low/CD16++ and
CD14++/CD16neg/low monocytes (Fig. 1A; dashed and solid boxes
FccRIIIa on Monocytes in Rheumatoid Arthritis
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respectively). The CD16 geometric mean fluorescence intensity
(MFI) and the percentage of CD16 positive cells were determined.
Analysis of TNF production
Thawed cryopreserved peripheral blood mononuclear cells
(PBMC) were incubated for 1 hour at 37uC with 1 mg/ml LPS
(Sigma-Aldrich, Dorset, UK) or 100 mg/ml heat-aggregated
immunoglobulin (HAG; soluble immunoglobulin (Novartis, Han-
over, Germany) incubated for 1 hour, 63uC) prior to addition of a
Monensin protein transport inhibitor (GolgistopTM, BD Biosci-
ences, Oxford, UK) and further incubation for 3 hours at 37uC in
5% CO2. Cells were washed and incubated with anti-CD14-
PerCP (30 min, 4uC in the dark) followed by washing and
incubation with LeucopermTM fixing reagent A (Serotec, Oxford,
UK) (15 minutes, room temperature in the dark). The cells were
washed and incubated with anti-TNF-PE or IgG1-PE (Serotec,
Oxford, UK) in the presence of LeucopermTM permeabilisation
buffer B (30 min, room temperature in the dark) before washing
and resuspending in PBS-BSA for immediate analysis (Becton
Dickinson LSRII). Monocytes were identified by FSC/SSC and
CD14 expression. The geometric MFI of TNF staining was
determined for all CD14-positive monocytes.
Figure 1. CD16 expression on peripheral blood monocytes in healthy control and RA patients. Example flow cytometric analysis of
peripheral blood monocytes from a single healthy control subject (A) and a long-standing RA patient (B). Monocytes were initially gated based on
light forward and side scatter (gated on monocytes and the upper portion of lymphocytes). Within this population, monocyte subsets were
distinguished by their staining with antibodies to CD14 and CD16. Examples of the separate gates created around the CD14low/CD16++ populations
(dashed boxes) and the CD14++/CD16neg/low population (solid boxes) are shown. The same samples stained with anti-CD14-PerCP and IgG1-
phycoerythrin (PE) isotype control in place of anti-CD16-PE were used to set gates. CD14neg/CD16++ cells were excluded from the CD14low/CD16++
based on gates set using staining with IgG2a-PerCP isotype control. (C) CD16 expression levels (MFI units) on CD14++ monocytes in control (n = 40),
early RA (n = 42) and long-standing RA patients (n = 38). (D) Percentage of CD14++ monocytes expressing CD16 in the same healthy control, early RA
and long-standing RA patients. Box plots represent median and upper and lower quartiles and dots represent outliers. Statistics; Mann-Whitney U
test.
doi:10.1371/journal.pone.0028918.g001
FccRIIIa on Monocytes in Rheumatoid Arthritis
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Genotyping
EDTA blood samples were frozen for DNA extraction and
genotyping. FCGR3A genotyping (FCGR3A-158F/V) was carried
out by direct sequencing of the PCR product [44,45].
Statistical Analysis
Data are summarised in box-plot diagrams (median and
interquartile ranges (IQR)) and compared using the Mann-
Whitney U test. Spearman’s test was used for correlations (p
values ,0.05 statistically significant). Wilcoxon signed-ranks test
was used for paired data samples. Potential differences in baseline
characteristics for EULAR non-responders compared with
moderate or good EULAR responders by week 14 were examined
to identify baseline characteristics that might influence response.
Analysis was performed using SPSS 15.0 for windows (Chicago,
Illinois, USA).
Results
Monocyte CD16 expression in healthy controls and RA
patients
Peripheral blood leukocytes from long-standing RA patients,
early-RA patients and unrelated healthy controls were examined
for CD16 expression on CD14low and CD14++ monocytes using
flow cytometry (Fig. 1). The percentage of CD14low/CD16++
monocytes among total CD14-positive cells in long-standing RA
patients (median 7.98% (IQR 3.6 to 9.6), n = 38) was not
significantly different from control subjects (median 6.51% (IQR
4.4 to 10.4), n = 40) (p = 0.305; Mann-Whitney U). There was no
significant difference in CD16 expression (MFI units) on CD14low/
CD16++ monocytes between healthy controls (median 927 (IQR
578-999)) and long-standing RA patients (median 1127 (IQR 953-
1581), (p = 0.299)). More strikingly, the CD14++/CD16neg/low
subset expressed variable levels of CD16; most CD14++ monocytes
in healthy control subjects were negative/low for CD16 expression
(Fig. 1A). In RA patients, positive staining for CD16 was shown on
this subset (Fig. 1B; high CD16-expressing patient). Expression
levels were significantly higher in patients with long-standing
disease than in healthy controls (p = 0.002; Fig. 1C). CD16
expression levels in early-RA were intermediate between healthy
control and long-standing RA patients and were not significantly
different from either (p = 0.94, p = 0.086, respectively). The
percentages of CD14++ monocytes expressing CD16 was also
higher in patients with long-standing disease than healthy controls
(p = 0.0014; Fig. 1D). Early-RA patients were not significantly
different than healthy controls in percentages of CD16 positive
CD14++ monocytes, but were significantly different from long-
standing RA patients (p = 0.22 and 0.008 respectively; Fig. 1D).
There was no correlation between CD16 expression levels on
CD14++ monocytes and increasing age in control subjects
(p = 0.13, Fig. 2A), no significant difference when control subjects
were stratified according to gender (p = 0.23, Fig. 2B). There was
no correlation with the level of inflammation (CRP (p = 0.485,
Fig. 2C) or ESR (p= 0.569, Fig. 2D)) in early and late RA patients.
TNF production from CD14-positive monocytes
TNF production triggered by LPS or IC stimulation (HAG) was
measured by intracellular staining of CD14–expressing monocytes
(Fig. 3A). LPS stimulation elicited TNF production by CD14-
expressing monocytes at a similar level between control (n = 8) and
Figure 2. Correlation of age, gender, CRP and ESR with FccRIIIa/CD16 expression on CD14++ monocytes. (A) Healthy control subjects
across a range of ages (x-axis) were tested for CD16 expression levels (MFI units, y-axis) on the CD14++ monocyte subset. (B) Healthy control subjects
were stratified according to gender and levels of CD16 expression examined. (C) CRP levels in long-standing RA patients (closed points) and early RA
patients (open points) were tested at the time of donating blood sample and examined for correlation with CD16 expression levels (MFI units, y-axis).
(D) ESR values (x-axis) were measured in early RA patients only and examined for correlation with CD16 expression level (MFI units, y-axis). Statistics;
Spearman’s correlation.
doi:10.1371/journal.pone.0028918.g002
FccRIIIa on Monocytes in Rheumatoid Arthritis
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RA (n= 8) cryopreserved PBMC (Fig. 3B). RA monocytes (n = 15)
demonstrate greater TNF production on HAG stimulation than
controls (p,0.001, Fig. 3B). The extent of HAG-stimulated
intracellular TNF staining in RA patients was correlated with the
percentage of CD14++monocytes expressing CD16 (r = 0.813,
p,0.001; Fig. 3C).
CD16pos expression on CD14++ monocytes is predictive
of response to methotrexate treatment
Clinical predictors of CD16 expression level in RA patients.
Patient demographics of a cohort of early RA patients are shown
in Table 1. The influence that the main baseline patient
characteristics have on CD16 expression levels on CD14++
monocytes are shown in Figure 4. Baseline CD16 expression on
CD14++ monocytes was not influenced by age (rho= 0.266,
p = 0.057 Fig. 4B), baseline DAS28ESR scores (rho= 0.041;
p = 0.743, Fig. 4F) or symptom duration up to one year
(rho= 0.262, p= 0.816 Fig. 4G). There was no significant
difference in CD16 expression on CD14++ monocytes in early
RA patients stratified according to gender (p = 0.437, Fig. 4A),
smoking status (current smoker vs. non-smoker p= 0.258, Fig. 4C),
the presence of autoantibodies (CCP pos vs. neg p= 0.082, RF pos
vs. neg p= 0.610, Fig. 4D and Fig. 4E respectively), or the
presence or absence of hand or foot erosions at presentation
(p = 0.327, Fig. 4H and p= 0.70, Fig. 4I respectively). Genetic
polymorphisms within the FCGR3A (FCGR3A-158F/V) gene did
not influence absolute FccRIIIa/CD16 expression level in early
RA patients (FV vs. FF p=0.506, Fig. 4J).
Clinical predictors of response to steroid/methotrexate
therapy. Within this steroid/methotrexate treated cohort,
baseline variable were examined for association with non- or
mod/good- EULAR response to therapy by 14 weeks. There was
no association between age, smoking status, presence of
autoantibodies and baseline DAS28ESR with response to
steroid/methotrexate therapy (Table 1). Significantly more
women were non-responders to steroid/methotrexate therapy
than men (p = 0.03, Table 1). The expression of CD16 on CD14++
monocytes prior to initiation of therapy in early-RA patients was
found to be predictive of response to methotrexate; mean CD16
expression on CD14++ monocytes was significantly higher in non-
responders compared to moderate and good responders
(p = 0.0009, Table 1). Thus, the percentage of CD14++
monocytes expressing CD16 at baseline was significantly
different between patients classified as EULAR non-responders
Figure 3. TNF Intracellular staining in CD14 positive monocytes from healthy control and RA patients. A) Thawed A) Cryopreserved
PBMC from control and RA patients were stimulated for 4hrs with LPS (1 mg/ml), heat-aggregated Ig [HAG] (100 mg/ml) or the absence of stimulation
(NS). Representative dot plots/histograms are shown for all treatments in a HC individual and for HAG stimulation in a RA patient (bottom panel).
Intracellular staining was performed using anti-human TNF-PE or isotype control-PE antibodies and MFI units of expression measured. B) Intracellular
staining for TNF in response to LPS (left panel) and HAG (right panel) in healthy control (HC, n = 8) and RA (n = 15) subjects. C) Correlation between
HAG-stimulated TNF intracellular staining and % CD16 positive monocytes in RA patients. The percentage of CD14++ monocytes expressing CD16 (x-
axis) and the MFI of anti-TNF-PE expression (y-axis) were determined by flow cytometry. Open diamonds represent early RA patient and shaded
diamonds represent long-standing RA patients. Correlation coefficient spearman’s rho= 0?813, p,0.001.
doi:10.1371/journal.pone.0028918.g003
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and moderate or good responders at 14 weeks post-methotrexate
therapy (Fig. 5A; p= 0.01 and p= 0.003 respectively). The
percentage of CD16 positive CD14++ monocytes at baseline was
also negatively correlated with the percentage reduction in
DAS28-ESR levels between 0-14 weeks (Fig. 5B; spearman’s
rho= -0.464, p = 0.003). When the analysis was stratified by
gender, CD16 was still significantly raised in EULAR non-
responders compared to moderate and good responders
(p = 0.0153) in female subjects. There were insufficient non-
responders to assess this in male subjects. The levels of CD16
Figure 4. Baseline characteristics of early RA patients prior to methotrexate therapy and correlations with CD16 expression. CD16
expression levels were examined on CD14++ monocytes for correlations with baseline characteristics in a cohort of early RA patients prior to
methotrexate therapy. Demographics examined were gender (A), age at baseline (B), smoking status (C), CCP autoantibody-positivity (D), RF-
positivity (E), baseline DAS28ESR (F), disease duration at initiation of therapy (G), foot erosions (H), hand erosions (I) and FCGR3A genotype (J).
Relationships between these baseline characteristics and EULAR responses are shown in Table 1.
doi:10.1371/journal.pone.0028918.g004
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expression (MFI units, data not shown) and the percentage of
CD14++ monocytes expressing CD16 were not significantly
changed at 2 or 14 weeks post-treatment compared with
baseline (p = 0.938 and p= 0.779 respectively; Wilcoxon signed
ranks test Fig. 5C).
Discussion
Monocytes are crucial players in the perpetuation of immune
responses and joint damage in RA. The CD14low monocyte subset
has previously been the major focus of attention in RA due to
reports of increased numbers in inflammatory diseases [28–31]
and following reports suggesting they are the main produces of
TNF in healthy controls [38]. However, in our current study we
found no significant difference in the proportions of the CD14low
monocyte subset, consistent with another study in this area [32], or
the level of FccRIIIa/CD16 expression between RA and control
subjects. In this study, we have demonstrated that the CD14++
monocyte subset in RA shows higher expression of FccRIIIa/
CD16 compared with healthy controls, as previously reported
[6,31,35–37]. This increased expression may result in a cell that is
more responsive to IgG-containing ICs with resultant cellular
activation. FccRIIIa/CD16 positive cells have been demonstrated
to be the main producers of TNF in response to LPS [26]. Indeed,
we have demonstrated that monocytes from RA patients show an
enhanced capacity to produce TNF in response to IgG-containing
ICs and the extent of TNF-production is correlated with the level
of FccRIIIa/CD16 expression on CD14++ monocytes. Therefore,
we propose that higher FccRIIIa/CD16 levels seen on CD14++
monocytes in RA may allow circulating ICs, found abundantly in
RA patients, to provide an inflammatory drive toward the
production of TNF and perpetuation of disease. Our data
demonstrated higher TNF production in response to ICs in RA
compared to healthy controls in contrast to recent work of Laurent
et al. who reported TNF production in response to IC was similar
between healthy controls and RA patients. The different results
may be accounted for by a greater increase in FccRIIIa/CD16
expression in RA relative to healthy controls in our study, which
may accentuate the difference in TNF production between the
groups. Furthermore, both studies used different experimental
methodologies that may have directly impacted on the results,
including method of monocyte isolation (unmanipulated PBMC
vs. positive selection of monocytes), different ICs (HAG vs. ACPA-
containing ICs derived from RA patients) and the measurement of
intracellular TNF after 4 hours by flow cytometry compared with
TNF release into the culture supernatant at 24 hours by ELISA.
Various other studies have previously attempted to address this
using a variety of ICs such as ACPA-containing [40], collagen-
containing IC [41] and PEG-precipitated IC [42]. These studies
were also unable to show any correlation between FccRIIIa/
CD16 and TNF production in response to the aforementioned IC,
but once again different sources of monocytes/monocyte-derived
macrophages were used (healthy controls) with a tendency for
longer culture duration and the measurement of TNF release into
culture supernatants, rather than intra-cellular TNF as employed
in the current study. The extent to which these methodological
differences directly impacted on the results from the different
studies is currently unknown.
FccR-mediated IC uptake, targeting into both MHC class I and
II antigen presentation pathways and cross-presentation of IC-
bound antigens has been demonstrated for FccRIIIa/CD16 [46–
49]. These CD14++/CD16pos cells also co-express chemokine
receptors and adhesion molecules thereby showing their capacity
to migrate rapidly to sites of inflammation. Studies have
demonstrated that magnetic-bead isolated CD16pos monocytes
adhere to activated endothelium and migrate into the joint more
efficiently than CD16neg monocytes due to increased adhesion
molecule and chemokine receptor expression [50]. In RA, this
CD16pos phenotype of cells becomes expanded due to increased
expression of CD16 on CD14++ monocytes and this cellular subset
may be associated with increased recruitment into the joint. We
have shown that monocytes from early-RA patients show
intermediate levels of FccRIIIa/CD16 expression between healthy
controls and RA patients, thus increased FccRIIIa/CD16
expression may become established as disease progresses. We
have shown that steroid/methotrexate treatment does not down
regulate FccRIIIa/CD16 expression, even in patients achieving
moderate/good clinical responses, consistent with previous
longitudinal studies [35]. Although the work by Wijngaarden
et al. 2005 showed a downregulation of CD16 after methotrexate
Table 1. Early RA patient baseline demographics and associations with response to steroid/methotrexate therapy.
Entire Cohort NR MOD/GOOD NR vs. MOD/GOOD
n=73 n=11 n=31 p value
Gender (% women) 69 91 64 P = 0.03 ({)
Age (median years) 51 59 48 P = 0.071 (w)
Smoking (% ever smoked) 45.7 66 38.4 P = 0.245 ({)
Smoking (% current smokers) 25.7 22.2 26.9 P = 1.0 ({)
CCP titre (mean) 204 229 194 P = 0.539 (w)
CCP positive (%) 86 90 84 P = 0.7448 ({)
RF titre (mean) 145 192 127 P = 0.156 (w)
RF positive (%) 80 80 80 P = 1.00 ({)
DAS28ESR baseline 5.6 5.20 5.74 P = 0.44 (w)
CD16 expression (mean MFI) 15.13 21.08 13.16 P = 0.0009 (w)
A cohort of early RA patients (n = 73) were recruited for investigation. Baseline characteristics of the cohort is summarised in column [Entire cohort]. Patients with EULAR
response data at week 14 post-initiation of therapy (n = 42) were furthermore split into non-responders [NR] or moderate/good responders [MOD/GOOD] and baseline
characteristics in each subgroup analysed separately. Statistically significant differences between the two EULAR response subgroups [NR vs. MOD/GOOD] were
examined. ({) fishers statistical test (w) mann-whitney U test.
doi:10.1371/journal.pone.0028918.t001
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therapy, this was a modest downregulation in the percentage of
FccRIIIa/CD16 positive cells and was not reproduced in MFI
expression levels. We hypothesise that in the context of persistent
autoantibody production in RA the CD14++/CD16pos cellular
subset may provide a continual drive to TNF-release and other
effector functions, such as phagocytosis and antigen-presentation
in the joint. Therefore, the presence of these monocytes may
represent an important part of the pathophysiology of autoanti-
body-positive RA, which may be relatively resistant to methotrex-
ate therapy and could be a potential therapeutic target.
We have demonstrated that increased FccRIIIa/CD16 expres-
sion on CD14++ monocytes in RA may be important in
determining non-response to methotrexate therapy. Expansion
of this CD14++/CD16pos subset may predict patients who will
have persistent circulating IC-driven TNF production, irrespective
of therapy, and as a consequence will demonstrate poorer
responses and may need more aggressive treatment with anti-
TNF/other biologics. FccRIIIa/CD16 expression is not correlated
with gender, DAS28-ESR score or the presence of systemic
inflammation, suggesting that FccRIIIa/CD16 may provide
additional information above current measures related to
response. However, this finding needs further validation, as
several high FccRIIIa/CD16 expressing patients demonstrated
adequate responses to methotrexate therapy.
Figure 5. FccRIIIa/CD16 expression on RA CD14++ monocytes pre- and post- methotrexate therapy. A) The percentage of CD16 positive
CD14++ monocytes was measured at baseline (y-axis) and correlated with patient responses to methotrexate treatment. Patients were classified at
week 14 post-initiation of therapy as non-responders (NR, n = 12), moderate (MOD, n= 12) or good (GOOD, n = 15) according to EULAR criteria and
compared using Mann Whitney U test. Dots represent outliers. (B) The percentage reduction in DAS28-ESR between 0 and 14 weeks post-initiation of
therapy (x-axis) and the % of CD14++ cells expressing CD16 at baseline (y-axis). Negative levels indicate increased DAS28ESR between baseline and
week 14. Statistics; Spearman’s correlation. C) The percentage of CD16 positive CD14++ monocytes was measured at baseline (wk0), 2 and 14 weeks
after initiation of steroid/methotrexate treatment in early DMARD-naı¨ve RA patients. Samples at 2 weeks mainly reflect influence of steroid treatment
whereas week 14 samples will mainly reflect the effect of methotrexate therapy. Wilcoxon signed ranks test used to compare paired samples pre- and
post- therapy.
doi:10.1371/journal.pone.0028918.g005
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We propose that CD14++/CD16pos monocytes warrant further
investigation due to the potential pathogenic importance of the
IC/FccRIIIa activation pathway in driving inflammatory respons-
es in RA. In addition, studies are needed to determine whether
monocyte FccRIIIa/CD16 expression levels could potentially be
used as a prognostic or predictive biomarker of response to
methotrexate therapy in RA. Furthermore, blockade of FccRIIIa/
CD16 represents an attractive target for future therapeutic
intervention.
Supporting Information
Figure S1 Validation of non-specific blockade using
immunoglobulin. A) Expression levels of staining (MFI units)
of IgG1-PE isotype control at increasing concentration of non-
specific binding blockade using soluble immunoglobulin (IgG mg/
ml). B) Expression levels of staining (MFI units) with CD16-PE
antibody clone 3G8 with increasing concentrations of non-specific
blocking using soluble immunoglobulin (IgG mg/ml) C) Compar-
ison of mean staining levels (MFI units) of CD16-PE clone 3G8 on
monocytes with or without immunoglobulin blockade (+/2IgG)
(data from 5 RA patients and 3 healthy controls).
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